[Use of orlistat (xenical) in the treatment of women with obesity and disorders of menstrual cycle].
Obesity poses a serious threat for health, being a risk factor for development of heart diseases, diabetes type II, tumors, and reproductive function failure. The aim of this study is to investigate the effect of orlistat (xenical) on the character of menstrual cycle and some metabolic indicators in women with obesity. 17 patients of reproductive age with I-III degree of obesity were investigated. The visceral type of obesity and disorders of menstrual cycle were observed in all patients: oligomenorrhea was observed in 9 (52.9%), amenorrhea in 4 (23.5%)and metrorrhagia in 4 (23.5 %) patients. All the patients received orlistat (xenical) 120 mg 3 times per day during 6 months. Orlistat (xenical) therapy results in significant reduction of body weight (12.3%), body mass index (13.3%), improvement of lipid and carbohydrates metabolisms. Normalization of hormonal levels was registered. As a result of all this the restoration of menstrual cycle and ovulation is registered. Orlistat (xenical) is effective in the treatment of women with obesity and menstrual cycle disorders.
Totoian
E S
ES
Frolova
N G
NG
Manasian
A S
AS
Akopian
M A
MA
Magevosian
A A
AA
Arutiunian
Zh S
ZhS
D000328:Adult; D000568:Amenorrhea / Q000453:epidemiology / Q000503:physiopathology*; D019440:Anti-Obesity Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015243:Cholesterol, VLDL / Q000378:metabolism; D005260:Female; D006801:Humans; D007783:Lactones / Q000494:pharmacology / Q000627:therapeutic use*; D008796:Metrorrhagia / Q000453:epidemiology / Q000503:physiopathology*; D009765:Obesity / Q000188:drug therapy* / Q000453:epidemiology; D000077403:Orlistat; D014280:Triglycerides / Q000378:metabolism
D019440:Anti-Obesity Agents; D015243:Cholesterol, VLDL; D007783:Lactones; D014280:Triglycerides; D000077403:Orlistat